Antiangiogenic therapies for mesothelioma

Jonathan E. Dowell, Hedy Lee Kindler

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Although treatment with standard chemotherapy for mesothelioma produces a modest survival benefit, most patients still die from their cancer. It is clear that the activity of conventional chemotherapy alone will never be sufficient to eradicate advanced disease. An improved understanding of the biology of mesothelioma has allowed the identification of rational molecular targets for therapeutic endeavors. Inhibition of angiogenesis is a particularly promising avenue that is being pursued actively in this disease. If activity is demonstrated in the current studies, the next step involves more trials of these targeted agents in combination with chemotherapy or other targeted agents. The hope is that with continued thoughtful development of these novel compounds, significant advances in the treatment of mesothelioma can be achieved.

Original languageEnglish (US)
Pages (from-to)1137-1145
Number of pages9
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Antiangiogenic therapies for mesothelioma'. Together they form a unique fingerprint.

Cite this